Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PHN-010 |
| Synonyms | |
| Therapy Description |
PHN-010 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PHN-010 | PHN010|PHN 010 | PHN-010 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |